Machine learning to identify biomarkers of response to immunotherapy in KRAS wildtype (KRASwt) non-small cell lung cancer (NSCLC). This is an ASCO Meeting Abstract from the 2026 ASCO Annual Meeting I.

ALK, anaplastic lymphoma kinase; BMI, body mass index; CI, confidence interval; ECOG PS, Eastern Cooperative Oncology Group performance status; EGFR, epidermal growth factor receptor; irAE, ...

// file, You can obtain one at https://mozilla.org/MPL/2.0/. // Please pull this list from, and only from https://publicsuffix.org/list/public_suffix_list.dat ...

New CY Series is designed to achieve exceptional levels of inspection accuracy while maintaining high speed manufacturing. Antares Vision Group will offer live demonstrations of an integrated line ...

In the hallowed silence of the National Heroes Acre, names are etched in granite, preceded by a title that once commanded absolute reverence: “Doctor.” But as we peel back the layers of Zimbabwe’s ...

GSK’s R&D foundation is strengthened through AI collaborations and with acquired late-phase assets promising near-term profits. Credit: Magda Wygralak/Shutterstock.com Early year artificial ...

Welcome to the first day of the 44th JPMorgan Healthcare Conference. I'm Richard Vosser, European pharma analyst at JPMorgan. It's my great pleasure to introduce argenx CEO, Timothy Van Hauwermeiren.

Despite immune checkpoint inhibitors(ICIs) significantly improve clinical outcomes in patients with advanced non-small cell lung cancer (aNSCLC), disease progression ...

Five-Year Survival Outcomes With Atezolizumab After Chemotherapy in Resected Stage IB-IIIA Non–Small Cell Lung Cancer (IMpower010): An Open-Label, Randomized, Phase III Trial In this global phase III ...

Fudan University Shanghai Cancer Center, Shanghai, China.

Journal of Nuclear Medicine June 2024, jnumed.124.267434; DOI: https://doi.org/10.2967/jnumed.124.267434 These aggregative approaches raise an interesting question ...